AptarGroup (ATR)
NYSE:ATR
Top Page
AptarGroup
(NYSE:ATR)
Select Model
Select Model
Rating:65Neutral
Price Target:
$139.00
▲(6.10% Upside)
Action:DowngradedDate:03/18/26
The score is driven primarily by solid financial performance (steady growth, resilient margins, and manageable leverage), partially offset by weak technical momentum (below key moving averages with negative MACD). Valuation is reasonable, while the latest earnings call and CEO transition add a mixed but generally stable backdrop due to reaffirmed guidance, productivity actions, and buybacks versus near-term margin and cost headwinds.
Positive Factors
Pharma pipeline & approvals
Regulatory approvals (e.g., CARDAMYST) and multiple Pharma partnerships signal durable, validation-driven wins. Regulatory-grade device supply and long qualification cycles create multi-year commercial commitments, high switching costs and predictable revenue from commercialized drug programs.
Negative Factors
Emergency medicine destocking
A ~$65M destocking impact concentrated in H1 reduces high-margin Pharma revenue and compresses near-term profitability. Even if temporary, the timing can delay margin recovery, weaken cash flow cadence and complicate resource allocation for commercialization and productivity investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Pharma pipeline & approvals
Regulatory approvals (e.g., CARDAMYST) and multiple Pharma partnerships signal durable, validation-driven wins. Regulatory-grade device supply and long qualification cycles create multi-year commercial commitments, high switching costs and predictable revenue from commercialized drug programs.
Read all positive factors
AptarGroup (ATR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.51B
Dividend Yield1.5%
Average Volume (3M)485.52K
Price to Earnings (P/E)20.4
Beta (1Y)0.59
Revenue Growth2.50%
EPS Growth25.05%
CountryUS
Employees13,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.25
Shares Outstanding64,379,740
10 Day Avg. Volume394,663
30 Day Avg. Volume485,517
Financial Highlights & Ratios
PEG Ratio3.60
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue2.53
Enterprise Value/Gross Profit8.56
Enterprise Value/Ebitda11.50
Forecast
1Y Price Target
$153.75Price Target Upside17.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)5.59
Revenue Forecast (FY)$3.94B
AptarGroup Business Overview & Revenue Model
Company Description
AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates t...
How the Company Makes Money
AptarGroup makes money primarily by manufacturing and selling proprietary dispensing, closure, and drug-delivery components to business customers (e.g., pharmaceutical companies and consumer packaged goods brand owners). Its revenue model is large...
AptarGroup Earnings Call Summary
Earnings Call Date:Feb 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The call presented a mix of clear operational and commercial strengths—notably strong Q4 revenue growth, sustained Pharma pipeline momentum (including FDA approval of CARDAMYST), meaningful tooling and commercial wins in Beauty and Closures, solid capital returns and a healthy balance sheet—while also disclosing significant near-term margin pressures driven by emergency medicine destocking (~$65 million headwind), operational disruptions in Beauty and Closures, higher interest and tax expenses, and a sizable Q4 EPS decline. Management emphasized that many negative items are transitory, expects sequential margin improvement through 2026 and reaffirmed productivity programs and buyback flexibility. Overall, positive revenue and pipeline momentum are meaningfully offset by near-term margin and cost challenges, leaving a balanced outlook.Positive Updates
Strong Q4 Revenue Growth
Reported sales for Q4 grew 14% year-over-year to $963 million (from $848 million); core sales increased 5%, reflecting healthy underlying demand across the portfolio.
Negative Updates
Material Margin Compression in Q4
Consolidated adjusted EBITDA margin declined by ~320 basis points to 19.8% in Q4; consolidated gross margins declined roughly 371 basis points year-over-year, driven by product mix and production impacts in Beauty and Closures and the high-margin emergency medicine decline.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Q4 Revenue Growth
Reported sales for Q4 grew 14% year-over-year to $963 million (from $848 million); core sales increased 5%, reflecting healthy underlying demand across the portfolio.
Read all positive updates
Company Guidance
Management reaffirmed its guidance with Q1 adjusted EPS of $1.13–$1.21 (assumes an effective tax rate of 21%–23% and a EUR/USD of $1.18), full‑year 2026 capital expenditures of $260–$280M and depreciation & amortization of $320–$330M, and a ~ $65M 2026 revenue headwind from emergency medicine (roughly 70% in H1 vs. 30% in H2) that will weigh on margins early in the year but is expected to moderate in H2; the company is offsetting pressure with structural productivity savings “well north of $100M,” expects full‑year performance to be within long‑term Pharma targets (core sales 7%–11% and adjusted margins 32%–36%), has a refreshed $600M share‑repurchase authorization, and noted higher interest costs tied to the stronger rate environment and its recently issued $600M 4.75% senior notes due March 2031.AptarGroup Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
77
Positive
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.78B | 3.58B | 3.49B | 3.32B | 3.23B |
| Gross Profit | 1.12B | 1.36B | 1.26B | 1.16B | 1.16B |
| EBITDA | 831.48M | 777.45M | 663.84M | 609.41M | 586.79M |
| Net Income | 392.79M | 374.54M | 284.49M | 239.29M | 244.10M |
Balance Sheet | |||||
| Total Assets | 5.25B | 4.43B | 4.45B | 4.20B | 4.14B |
| Cash, Cash Equivalents and Short-Term Investments | 409.53M | 226.18M | 223.64M | 141.73M | 123.67M |
| Total Debt | 1.53B | 1.08B | 1.18B | 1.22B | 1.24B |
| Total Liabilities | 2.54B | 1.95B | 2.13B | 2.14B | 2.16B |
| Stockholders Equity | 2.67B | 2.47B | 2.31B | 2.05B | 1.97B |
Cash Flow | |||||
| Free Cash Flow | 299.58M | 349.22M | 256.84M | 163.00M | 55.51M |
| Operating Cash Flow | 570.00M | 643.41M | 575.24M | 478.62M | 363.44M |
| Investing Cash Flow | -330.64M | -396.72M | -324.46M | -295.64M | -457.24M |
| Financing Cash Flow | -78.26M | -225.34M | -171.55M | -162.10M | -81.52M |
AptarGroup Technical Analysis
Positive
131.01
Price Trends
132.46
Negative
127.21
Positive
132.39
Negative
Market Momentum
-0.22
Negative
57.76
Neutral
90.75
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATR, the sentiment is Positive. The current price of 131.01 is above the 20-day moving average (MA) of 126.47, below the 50-day MA of 132.46, and below the 200-day MA of 132.39, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 57.76 is Neutral, neither overbought nor oversold. The STOCH value of 90.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATR.
AptarGroup Risk Analysis
AptarGroup disclosed 28 risk factors in its most recent earnings report. AptarGroup reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AptarGroup Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $18.72B | 40.29 | 16.68% | 0.32% | 4.90% | -0.26% | |
65 Neutral | $8.51B | 20.41 | 14.67% | 1.50% | 2.50% | 25.05% | |
64 Neutral | $13.99B | 30.60 | 4.83% | ― | 5.06% | -4.47% | |
63 Neutral | $3.77B | 34.81 | 9.72% | 0.29% | 9.19% | 23.06% | |
60 Neutral | $6.91B | 188.46 | 2.37% | ― | 11.74% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $9.10B | -10.24 | -13.78% | 2.75% | -21.20% | -325.40% |
* Healthcare Sector Average
ATR
AptarGroup
131.01
-11.02
-7.76%
BAX
Baxter International
17.59
-9.84
-35.86%
COO
Cooper Co
71.61
-6.19
-7.96%
RGEN
Repligen
131.03
4.41
3.48%
WST
West Pharmaceutical Services
267.93
56.18
26.53%
STVN
Stevanato Group
14.77
-7.81
-34.58%
AptarGroup Corporate Events
Executive/Board Changes
AptarGroup Announces CEO Succession and Leadership Transition Plan
Positive
Mar 17, 2026
On March 16, 2026, AptarGroup announced that President and CEO Stephan Tanda will retire from his executive roles effective Sept. 1, 2026, with Aptar Pharma president Gael Touya appointed as his successor and expected to join the board at that tim...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.